Millennium Management
HEPA

Millennium Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Millennium Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-29
Closed -$91 – 5356
2020
Q3 		$91 Buy
+29
New +$104K ﹤0.01% 4239

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management's HEPA Position: Q4 2020 in Review

Millennium Management sold out of Hepion Pharmaceuticals (HEPA) in Q4 2020, closing a stake of 29 shares — an estimated $91 sold.

Millennium Management first reported a position in HEPA in Q3 2020 and held it in 1 quarter. The position peaked at $91 in Q3 2020. 29 funds tracked by Wall St. Rank hold HEPA as of Q4 2020.

  • Millennium Management reported no remaining Hepion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Millennium Management sold 29 Hepion Pharmaceuticals shares in Q4 2020, an estimated $91.
  • Millennium Management first reported a position in Hepion Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Millennium Management's Hepion Pharmaceuticals position peaked at $91 in Q3 2020.
  • 29 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q4 2020.

Based on Millennium Management's 13F filing for Q4 2020, filed 16 Feb 2021.